Holmes Biopharma, Inc.: Initiates Broker Relations Program

SCOTTSDALE, ARIZONA is pleased to announce that it has retained the services of Newport Capital Consultants, Inc., a California based consulting firm engaged in the provision of broker relations consulting expertise to private and public companies. Mr. Bryant, President, who has over 40 years of experience in the investment banking services industry, and his team of consultants are respected Associate Members of the National Investment Bankers Association (NIBA), as well as members of the Southern California Investment Association (SCIA). Newport Capital Consultants has advanced over 50 companies from the OTC Board to the AMEX and the NYSE. Many of these companies received significant funding from investors introduced by Newport Capital Consultants.

"The addition of Newport Capital Consultants will introduce Holmes Biopharma to a broader network of Investment bankers through their well established network,"

stated John Metcalfe, President and CEO.

About Holmes:

Holmes Biopharma, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services to the pharmaceutical industry and is actively involved in developing new drugs and drug delivery systems. Currently, clinics operate in Omaha, Nebraska USA, Toronto, Canada. and Kiev, Ukraine, Eastern Europe. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President, CEO

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contacts: Holmes Biopharma, Inc. John F. Metcalfe President, CEO 1-800-778-4990 Email: ir@holmesbiopharma.com Website: www.holmesbiopharma.com

Swiftsure (CE) (USOTC:HLMB)
Historical Stock Chart
From Apr 2024 to May 2024